Chun Yong, CEO at Reach7 Diabetes Studios
Today’s landscape of diabetes care is fraught with challenges: it’s a condition that’s often misunderstood by both patients and the healthcare system, highly prevalent, financially burdensome and frequently…
Continue Reading
What You Should Know:
– LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
– The comprehensive package includes both the GLP-1 medication…
Continue Reading
What You Should Know:
– Sequel Med Tech, a company developing state-of-the-art insulin delivery technologies, announced a commercial development agreement with Abbott.
– The collaboration aims for the future integration of Sequel’s twiist™ Automated Insulin Delivery…
Continue Reading
What You Should Know:
– Medtronic today announced its strategic decision to separate its Diabetes business into a new, independent, publicly traded company (“New Diabetes Company”).
– The move aims to create a more focused Medtronic,…
Continue Reading
Pharmaceutical and diagnostics giant Roche announced it will fund a $550 million diagnostic center in Indianapolis by 2030.The manufacturing hub will produce Roche’s continuous glucose monitoring (CGM) systems for diabetes management.
The center will include…
What You Should Know:
– Abbott, a provider of continuous glucose monitoring (CGM) biowearable technology, has announced a landmark agreement with Epic Systems, a major provider of electronic health records (EHR).
– The first-of-its-kind collaboration for…
Continue Reading
What You Should Know:
– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement.
–…
Continue Reading
Extended Wear CGM Innovation Redefines Diabetes Management
Dexcom has reached a significant milestone with FDA clearance for its G7 15-Day continuous glucose monitoring system for adults 18 and older. This next-generation device extends wear time…
What You Should Know:
– Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes…
Continue Reading
What You Should Know:
– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18…
Continue Reading
